Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland. The president ...

One of the more interesting aspects about President Donald Trump's recent tariffs is that ... one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Many investments Mr. Trump claims credit for predate his return to office or are based on vague future pledges. Here's a fact ...

In this article, we are going to take a look at where Eli Lilly and Company ... According to Cramer, Trump is willing to accept the negative impact on the market and the broader economy as ...

Eli Lilly CEO Dave Ricks urged the Trump administration to move fast on ... on tariffs or retaliatory tariffs would have a negative impact on not just Lilly but the entire pharmaceutical industry.

Ireland has become a major base for US pharma companies, including Pfizer, Eli Lilly and Johnson & Johnson. That’s bolstered the economies of individual towns and played a role in the country’s ...

The president said his executive order will require pharmaceutical companies to price drugs in the U.S. in line with the ...

Although AbbVie, Eli Lilly ... impact. Michaels noted "penalties in the government channel and with existing contracts in the commercial setting" as barriers to hiking drug prices. However, the ...

President Trump recently warned big drugmakers that ... the president warned that a "tariff wall" is coming. Although AbbVie, Eli Lilly, and Johnson & Johnson manufacture many of their products ...

Johnson & Johnson factored roughly $400 million into its 2025 guidance to account for the impact ... the Trump administration could unleash an even bigger threat than tariffs to AbbVie, Lilly ...